LETROZOLE AND RIBOCICLIB (KISQALI FEMARA CO-PACK) Nursing Considerations

Join NURSING.com to watch the full lesson now.

Included In This Lesson

Outline

What is the generic name?

LETROZOLE AND RIBOCICLIB

What is the Trade Name for LETROZOLE AND RIBOCICLIB?

KISQALI FEMARA CO-PACK

What are the Indications for LETROZOLE AND RIBOCICLIB?

  • 1 INDICATIONS AND USAGE The KISQALI ¬Æ FEMARA ¬Æ CO-PACK is indicated as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. KISQALI FEMARA CO-PACK, a co-packaged product containing ribociclib, a kinase inhibitor, and letrozole, an aromatase inhibitor, is indicated as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. ( 1 )

 

View Our Nursing Pharmacology Course


 

References: https://open.fda.gov/

 

Other Pharm Resources
Join NURSING.com to watch the full lesson now.